8-K: NovaBay CEO Resigns Amid 90% Stake Transfer

NovaBay Pharmaceuticals' CEO, David Lazar, resigned as a significant stake, representing approximately 90% of common stock, is being transferred to R01 Fund LP and Framework Ventures IV L.P.

Summary

• David Lazar resigned as Chief Executive Officer and a director of NovaBay Pharmaceuticals, Inc., effective upon the release of Escrow Funds to him.
• Mr. Lazar entered into a Securities Purchase Agreement with R01 Fund LP and Framework Ventures IV L.P. (the Purchasers) to transfer his holdings.
• The transfer includes 441,325 shares of Series D Non-Voting Convertible Preferred Stock and rights and obligations to purchase 268,750 shares of Series E Non-Voting Convertible Preferred Stock.
• These securities were originally acquired by Mr. Lazar from NovaBay pursuant to a Securities Purchase Agreement dated August 19, 2025.
• The transaction is contingent on stockholder approval of proposals 5 and 9, as set forth in the Proxy Statement, at the Company's 2025 Annual Meeting of stockholders to be held on October 16, 2025.
• Upon completion of the transaction, the Purchasers are expected to collectively beneficially own approximately 90% of NovaBay's outstanding common stock.

Sentiment

Score: 5

Explanation: The filing reports a significant change in ownership and leadership, which introduces both potential opportunities (new investment) and uncertainties (CEO departure, shareholder approval contingency). The 90% beneficial ownership by new investors is a major shift.

Positives

• The transaction facilitates a significant change in ownership structure, potentially bringing new strategic direction and capital to NovaBay Pharmaceuticals.
• The transfer of a large block of preferred stock and rights to new institutional investors (R01 Fund LP and Framework Ventures IV L.P.) could stabilize the company's ownership base and provide a clear path forward.

Negatives

• The resignation of David Lazar as CEO and a director indicates a significant leadership transition, which can introduce uncertainty.
• The transaction is subject to stockholder approval, introducing a contingency that could delay or prevent its completion.
• A single group of purchasers potentially owning approximately 90% of outstanding common stock could raise concerns about minority shareholder influence and corporate control.

Risks

• The Purchase is subject to customary closing conditions, including stockholder approval of proposals 5 and 9 at the 2025 Annual Meeting, which could prevent the transaction from closing.
• The effectiveness of David Lazar's resignation as CEO and director is contingent upon the release of Escrow Funds, introducing a potential delay or uncertainty in the leadership transition.

Future Outlook

The Purchasers are expected to collectively beneficially own approximately 90% of the outstanding common stock upon approval of the Investment Transaction and Related Transactions and completion of the First Closing and Final Closing.

Industry Context

This event signifies a major ownership restructuring and leadership change for NovaBay Pharmaceuticals. Such significant shifts can impact investor perception, strategic direction, and competitive positioning within the pharmaceutical or biotech industry, especially for smaller companies. It could signal either a distressed asset acquisition or a strategic investment by new players.

Management Changes

Related Party Transactions

• David Lazar, the resigning CEO and director, is the seller in the Securities Purchase Agreement, transferring securities he previously acquired from the Company.

Stakeholder Impact

• Shareholders: Significant change in beneficial ownership (approximately 90% by new investors) could impact future strategic direction, dividend policies, and minority shareholder influence. Requires their approval for the transaction.
• Management/Employees: Departure of CEO David Lazar signals a leadership transition, potentially leading to changes in corporate strategy and operations.
• Creditors: A major ownership change could alter the company's financial strategy and risk profile, potentially impacting creditors.

Next Steps

• Stockholders to vote on proposals 5 and 9 at the 2025 Annual Meeting on October 16, 2025.
• Release of Escrow Funds from the Escrow Agent to David Lazar.
• Completion of the First Closing and Final Closing of the Investment Transaction and Related Transactions.

Key Dates

Recommendation

The filing indicates a significant corporate restructuring with the CEO's resignation and a major ownership transfer. While new institutional investors acquiring an approximately 90% beneficial stake could bring stability and new strategic direction, the immediate future involves uncertainty surrounding leadership transition and the contingency of shareholder approval. Investors should hold to observe the outcome of the shareholder vote and the subsequent strategic direction under new ownership before making further investment decisions.

Keywords

NovaBay Pharmaceuticals, NBY, SEC Filing, 8-K, David Lazar, CEO Resignation, Director Resignation, Securities Purchase Agreement, Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, R01 Fund LP, Framework Ventures IV L.P., Stockholder Approval, Corporate Governance, Ownership Change, Investment Transaction